/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITES STATES./
MONTREAL, June 20 /CNW Telbec/ - OPMEDIC GROUP Inc. ("OPMEDIC GROUP")
(TSX: "OMG"), a healthcare-related service company providing facilities and
services to patients and surgeons, is pleased to announce that its division
PROCREA Cliniques has obtained Clinical Laboratory Improvement Amendments
("CLIA") Certification of Registration for its high-complexity cytogenetic and
genetic testing services. Cytogenetic services are designed to improve
healthcare as an aid in prenatal screening and can be performed on peripheral
blood, amniotic fluid and bone marrow. Genetic tests, on the other hand, are
offered in an antenatal fashion and are performed on peripheral blood.
Certification under CLIA is required for all clinical laboratories that
offer clinical testing services in the USA. This CLIA certification signifies
the intention of OPMEDIC GROUP Inc. to expand its clinical laboratory services
in the United States market.
"OPMEDIC GROUP's CLIA Certificate of Registration is the first step to
expand our commercial activities in the USA by providing high quality
innovative clinical services, faster turnaround times at competitive pricing"
said Dr. Pierre St-Michel, President & CEO of OPMEDIC GROUP Inc.
About OPMEDIC GROUP
OPMEDIC GROUP is a company incorporated under the laws of the Province of
Quebec which provides healthcare-related services including surgical
facilities and services to patients and surgeons (with its OPMEDIC division),
fertility treatments, medical imaging, laboratory services and diagnostic
procedures (with its PROCREA Cliniques division) and sperm banking services
(with its PROCREA Cryopreservation Centre subsidiary). OPMEDIC GROUP's Common
Shares trade on the Toronto Stock Exchange under the symbol "OMG".
This news release does not constitute an offer to sell or to solicitation
of an offer to buy any security and shall not constitute an offer,
solicitation or sale in any jurisdiction in which such offering would be
unlawful. This news release contains certain forward-looking statements that
reflect the current views and/or expectations of OPMEDIC GROUP with respect to
its performance, business and future events. Such statements are subject to a
number of risks, uncertainties and assumptions. Actual results and events may
The Content of this press release has not been approved by nor submitted
to the TSX which assumes no liability therefore.
For further information:
For further information: Paulo BOUCA, Vice President Business
Development and Chief Operating Officer, (514) 345-8535, x 2254,